Upregulation of CDKN3 is considered to be a key factor in promoting tumor cell proliferation and malignant transformation in ovarian cancer, cervical cancer, lung adenocarcinoma and leukemia, and is a potential molecular target for antitumor therapy (33–36). The gene discussed is CDKN3; the disease is leukemia.